Trial: Pre-Exposure Prophylaxis Initiative [iPrEx]
Phase: III
Product Being Tested: Daily oral TDF/FTC (Truvada®)
Sponsor, funder, developer, collaborator: National Institute of Health, Bill and Melinda Gates Foundation, Fenway Community Health, San Francisco Department of Public Health
Total participants: 2,499
Countries: Brazil, Ecuador, Peru, South Africa, Thailand, US
Trial sites in US: Boston, MA
Results expected: Announced in Q4 2010. For more information visit theGlobal iPrEx page or AVAC's iPrEx page


Trial: Bangkok Tenofovir Study [CDC 4370]
Phase: II/III
Product Being Tested: Daily oral TDF
Sponsor, funder, developer, collaborator: US Centers for Disease Control and Prevention
Total participants: 2,400
Countries: Thailand
Trial sites in Thailand: Bangkok
Results expected: Q4 2010
Back to Top ↑